Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Krystal Biotech, Inc. - Common Stock (NQ:KRYS)

191.89 -1.10 (-0.57%)
Streaming Delayed Price Updated: 11:33 AM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Krystal Biotech, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Insider Confidence Shines: Krystal Biotech and Growth Stocks with Strong Management Stakes Navigate Volatile Markets
The U.S. stock market is currently a landscape of contrasting forces, with robust bank earnings providing a bedrock of stability against the backdrop of persistent trade tensions with China and... 
Via MarketMinute
Topics Artificial Intelligence World Trade
What's Driving the Market Sentiment Around Krystal Biotech Inc?
 
Via Benzinga
6 Stocks Goldman Sachs Says Are Poised For Potential Acquisition In Next 12 Months — Including A Huge 200% Winner
Goldman Sachs has highlighted six stocks that have a high probability of being acquisition targets in the next year. 
Via Benzinga
Earnings Scheduled For August 4, 2025
 
Via Benzinga
Earnings Outlook For Krystal Biotech
 
Via Benzinga
Analyst Expectations For Krystal Biotech's Future
 
Via Benzinga
Peering Into Krystal Biotech's Recent Short Interest
 
Via Benzinga
If You Invested $1000 In Krystal Biotech Stock 5 Years Ago, You Would Have This Much Today
Krystal Biotech (NASDAQ: KRYS) has outperformed the market over the past 5 years by 16.54% on an annualized basis producing an average annual return of 31.18%. Currently, Krystal Biotech has a market... 
Via Benzinga
Here's How Much $100 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today
 
Via Benzinga
FDA Expands Krystal Biotech Vyjuvek's Label Allowing Newborns Access To Gene Therapy For Blistering Skin
The FDA approved Krystal Biotech's Vyjuvek label update, expanding treatment to newborns and offering flexible wound care based on real-world patient data. 
Via Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today
 
Via Benzinga
A Glimpse Into The Expert Outlook On Krystal Biotech Through 10 Analysts
 
Via Benzinga
What Does the Market Think About Krystal Biotech?
 
Via Benzinga
Earnings Scheduled For May 6, 2025
 
Via Benzinga
If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today
 
Via Benzinga
What 8 Analyst Ratings Have To Say About Krystal Biotech
 
Via Benzinga
Crude Oil Falls 1.5%; ON Semiconductor Shares Plunge After Q2 Results
 
Via Benzinga
Krystal (KRYS) Q2 Profit Jumps 143%
Via The Motley Fool
KRYSTAL BIOTECH INC (NASDAQ:KRYS) Q2 2025 Earnings Beat Estimates as VYJUVEK Drives Strong Revenue Growth
Krystal Biotech (KRYS) Q2 2025 earnings beat estimates with $96M revenue and $1.29 EPS, driven by VYJUVEK success. Shares rose 4% pre-market. 
Via Chartmill
Topics Earnings
Here's How Much $100 Invested In Krystal Biotech 5 Years Ago Would Be Worth Today
 
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Here's How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years
 
Via Benzinga
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
Via The Motley Fool
Topics Artificial Intelligence
Demystifying Krystal Biotech: Insights From 7 Analyst Reviews
 
Via Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
 
Via Benzinga
$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
Via Benzinga
The Analyst Verdict: Krystal Biotech In The Eyes Of 12 Experts
 
Via Benzinga
Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore
These 3 pharma stocks have oversold RSIs and solid analyst support, setting up potential bounce-back trades through this week and next 
Via MarketBeat
Topics Earnings
If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today
 
Via Benzinga
Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease
Abeona's Zevaskyn secures timely FDA nod, priced at $3.1 million, with 2025 sales now forecast at $31.6 million and peak U.S. revenue projected at $600 million. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.